Finoriq research workspace
AYTU BIOPHARMA, INC (AYTU) SEC Filings & Filing Highlights
AYTU BIOPHARMA, INC offers prescription products for the treatment of attention deficit. Review AYTU SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
- Company
- AYTU BIOPHARMA, INC (AYTU)
- Ticker
- AYTU
- Market Cap
- $23.4M
- Latest Price
- $2.18
- Industry
- Biotech & Pharma
AYTU BIOPHARMA, INC (AYTU) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for AYTU BIOPHARMA, INC (AYTU).
| Event | Form | Date |
|---|---|---|
| Termination of Material Definitive AgreementTermination of Material Definitive Agreement | 8-K1.02 | 2026-06-25 |
| AYTU BIOPHARMA, INC: Earnings or resultsOn May 13, 2026, Aytu BioPharma, Inc. (the “Company”) issued a press release announcing its fiscal 2026 third quarter operational and finan... | 8-K2.02 | 2026-05-13 |
| See the disclosures in Item 1.01 of this report, which are incorporated herein by referenceSee the disclosures in Item 1.01 of this report, which are incorporated herein by reference | 8-K3.03 | 2026-04-02 |
| See the disclosures in Item 1.01 of this report, which are incorporated herein by referenceSee the disclosures in Item 1.01 of this report, which are incorporated herein by reference | 8-K3.02 | 2026-04-02 |
| See the disclosures in Item 1.01 of this report, which are incorporated herein by referenceSee the disclosures in Item 1.01 of this report, which are incorporated herein by reference | 8-K2.02 | 2026-04-02 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.